MSA prions exhibit remarkable stability and resistance to inactivation
- 1.6k Downloads
In multiple system atrophy (MSA), progressive neurodegeneration results from the protein α-synuclein misfolding into a self-templating prion conformation that spreads throughout the brain. MSA prions are transmissible to transgenic (Tg) mice expressing mutated human α-synuclein (TgM83+/−), inducing neurological disease following intracranial inoculation with brain homogenate from deceased patient samples. Noting the similarities between α-synuclein prions and PrP scrapie (PrPSc) prions responsible for Creutzfeldt–Jakob disease (CJD), we investigated MSA transmission under conditions known to result in PrPSc transmission. When peripherally exposed to MSA via the peritoneal cavity, hind leg muscle, and tongue, TgM83+/− mice developed neurological signs accompanied by α-synuclein prions in the brain. Iatrogenic CJD, resulting from PrPSc prion adherence to surgical steel instruments, has been investigated by incubating steel sutures in contaminated brain homogenate before implantation into mouse brain. Mice studied using this model for MSA developed disease, whereas wire incubated in control homogenate had no effect on the animals. Notably, formalin fixation did not inactivate α-synuclein prions. Formalin-fixed MSA patient samples also transmitted disease to TgM83+/− mice, even after incubating in fixative for 244 months. Finally, at least 10% sarkosyl was found to be the concentration necessary to partially inactivate MSA prions. These results demonstrate the robustness of α-synuclein prions to denaturation. Moreover, they establish the parallel characteristics between PrPSc and α-synuclein prions, arguing that clinicians should exercise caution when working with materials that might contain α-synuclein prions to prevent disease.
Keywordsα-synuclein Neurodegeneration Propagation Proteinopathies Transmission models
We thank the Hunters Point animal facility staff for breeding and caring for the mice used in this study and Martin Ingelsson (Uppsala University) for providing control tissue.
ALW, SHO, and SBP designed research; ALW, SAK, SP, YF, and AO performed research; AA, DAM, GMH, LTM, and SMG contributed new reagents/analytic tools; ALW, SAK, SP, SHO, and SBP analyzed data; and ALW, SHO, and SBP wrote the paper.
Compliance with ethical standards
Conflict of interest
The Institute for Neurodegenerative Diseases has a research collaboration with Daiichi Sankyo (Tokyo, Japan). SBP is the chair of the Scientific Advisory Board of Alzheon, Inc., which has not contributed financial or any other support to these studies.
Animals were maintained in an AAALAC-accredited facility in compliance with the Guide for the Care and Use of Laboratory Animals. All procedures used in this study were approved by the University of California, San Francisco, Institutional Animal Care and Use Committee.
This work was supported by grants from the National Institutes of Health (AG002132 and AG031220), as well as by gifts from the Glenn Foundation, Daiichi Sankyo, the Dana Foundation, the Henry M. Jackson Foundation, the Mary Jane Brinton Fund, the Rainwater Charitable Foundation, the Schott Foundation for Public Education, and the Sherman Fairchild Foundation. The Massachusetts Alzheimer’s Disease Research Center is supported by the National Institutes of Health (AG005134); the Parkinson’s UK Brain Bank at Imperial College London is funded by Parkinson’s UK, a charity registered in England and Wales (948776) and in Scotland (SC037554); and the Sydney Brain Bank is supported by Neuroscience Research Australia and the University of New South Wales. Glenda M. Halliday is a National Health and Medical Research Council of Australia Senior Principal Research Fellow (1079679).
- 18.Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba J-P, Ulmer H, Pellecchia MT et al (2006) Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 21:179–186CrossRefPubMedGoogle Scholar
- 21.Giles K, Woerman AL, Berry DB, Prusiner SB (2017) Bioassays and inactivation of prions. In: Prusiner SB (ed) Prion biology. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
- 32.Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ (1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 155:9–15CrossRefPubMedGoogle Scholar
- 34.Meissner WG, Laurencin C, Tranchant C, Witjas T, Viallet F, Guehl D, Damier P, Houeto J-L, Tison F, Eusebio A et al (2016) Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord 24:69–75CrossRefPubMedGoogle Scholar
- 39.Poisson M, Magdelenat H, Foncin JF, Bleibel JM, Philippon J, Pertuiset B, Buge A (1980) Récepteurs d’cestrogénes et de progestérone dans les méningiomes. Rev Neurol (Paris) 136:193–203Google Scholar
- 40.Prusiner SB, Woerman AL, Rampersaud R, Watts JC, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH et al (2015) Evidence for α-synuclein prions causing multiple system atrophy in humans with signs of Parkinson’s disease. Proc Natl Acad Sci USA 112:E5308–E5317CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR et al (2014) Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA 111:10732–10737CrossRefPubMedPubMedCentralGoogle Scholar